Ameriprise
LFCR icon

Ameriprise’s Lifecore Biomedical LFCR Stock Holding History

Ameriprise’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-33,413
Closed -$371K – 3992
2021
Q4 		$371K Sell
33,413
-580
-2% -$5.63K ﹤0.01% 3609
2021
Q3 		$313K Sell
33,993
-65,322
-66% -$711K ﹤0.01% 3548
2021
Q2 		$1.12M Buy
99,315
+88,136
+788% +$1.02M ﹤0.01% 3182
2021
Q1 		$118K Buy
+11,179
New +$126K ﹤0.01% 3758
2019
Q3 		– Sell
-10,234
Closed -$96K – 3740
2019
Q2 		$96K Buy
+10,234
New +$103K ﹤0.01% 3664
2013
Q4 		– Sell
-1,616
Closed -$20K – 5303
2013
Q3 		$20K Sell
1,616
-61,650
-97% -$860K ﹤0.01% 4417
2013
Q2 		$835K Buy
+63,266
New +$875K ﹤0.01% 2676

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise's LFCR Position: Q1 2022 in Review

Ameriprise sold out of Lifecore Biomedical (LFCR) in Q1 2022, closing a stake of 33,413 shares — an estimated $371K sold.

Ameriprise first reported a position in LFCR in Q2 2013 and held it in 7 quarters. The position peaked at $1.12M in Q2 2021. 97 funds tracked by Wall St. Rank hold LFCR as of Q1 2022.

  • Ameriprise reported no remaining Lifecore Biomedical position as of Q1 2022 after selling out during the quarter.
  • Ameriprise sold 33,413 Lifecore Biomedical shares in Q1 2022, an estimated $371K.
  • Ameriprise first reported a position in Lifecore Biomedical in Q2 2013 and held it in 7 quarters.
  • Ameriprise's Lifecore Biomedical position peaked at $1.12M in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2022.

Based on Ameriprise's 13F filing for Q1 2022, filed 16 May 2022.